Stifel Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12

Benzinga · 1d ago
Stifel analyst Laura Prendergast initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $12.